An international Norton Rose Fulbright life sciences transactions team recently advised GSK in its development agreement and R&D collaboration with Propeller Health for GSK’s Ellipta® dry powder inhaler.
Under the terms of this non-exclusive agreement, Propeller Health will develop and manufacture a custom sensor for the Ellipta inhaler for use in certain GSK clinical studies in asthma and COPD. In the studies, the sensor will automatically collect and record data on the inhaler’s usage, wirelessly transmitting the information to a central data repository for analysis by GSK’s clinical researchers. The sensor technology will be used to provide greater insights into adherence patterns across patient populations and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes.
GSK retains an option to negotiate exclusive commercialization rights to the sensor for use with its marketed portfolio of respiratory medicines administered using the Ellipta inhaler.
New York life sciences partner Andres Liivak led the team representing GSK, working closely together with London senior associate George Cameron. Additional Norton Rose Fulbright lawyers providing support included US Head of IP Transactions and Patent Prosecution Gina Shishima, Global Head of Financial Restructuring and Insolvency Louis Strubeck, London privacy and cyber security partner Ffion Flockhart and London trainee Alex Smyth-Osbourne.
Propeller Health announced in November 2016 that it had been successful in obtaining FDA clearance for the sensor.